LPCN

Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products. The Company's primary development programs are based on oral delivery solutions for bioavailable drugs. The Company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitates lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminates gastrointestinal interactions that limit bioavailability. Its lead product candidate, TLANDO, is an oral testosterone replacement therapy. Its additional pipeline includes, an oral androgen therapy for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, LPCN 1144; a once daily oral testosterone replacement therapy, TLANDO XR (LPCN 1111); an androgen therapy for the treatment of NASH cirrhosis, LPCN 1148, and an oral therapy for the prevention of preterm birth, LPCN 1107.